Get the Stockscreener App
39.35
0.51%
-0.20
Dianthus Therapeutics Inc stock is traded at $39.35, with a volume of 960.24K.
It is down -0.51% in the last 24 hours and up +66.95% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$39.55
Open:
$39.55
24h Volume:
960.24K
Relative Volume:
1.56
Market Cap:
$1.27B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-12.11
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+3.91%
1M Performance:
+66.95%
6M Performance:
+116.92%
1Y Performance:
+43.72%
1-Day Range:
$38.73
$40.16
1-Week Range:
$35.50
$40.16
52-Week Range:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
39.35 | 1.57B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - MSN
How Dianthus Therapeutics Inc. stock benefits from global expansionJobs Report & Weekly Breakout Opportunity Watchlist - newser.com
Dianthus Therapeutics stock hits 52-week high at 40.0 USD By Investing.com - Investing.com South Africa
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics stock hits 52-week high at 40.0 USD - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year HighHere's Why - MarketBeat
What drives Dianthus Therapeutics Inc stock priceTechnical Resistance Breaks & Access Free Tools and Start Investing - earlytimes.in
Will Dianthus Therapeutics Inc. continue its uptrendPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Volume spikes in Dianthus Therapeutics Inc. stock – what they meanWeekly Gains Report & Safe Capital Growth Trade Ideas - newser.com
Why retail investors pile into Dianthus Therapeutics Inc. stockPortfolio Growth Summary & Expert Approved Momentum Ideas - newser.com
Can Dianthus Therapeutics Inc. stock resist sector downturnsJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - newser.com
Why Dianthus Therapeutics Inc. is moving todayEarnings Beat & AI Optimized Trade Strategies - newser.com
Is Dianthus Therapeutics Inc. (87E) stock a buy before new product rolloutEarnings Miss & Expert Verified Movement Alerts - newser.com
What indicators show strength in Dianthus Therapeutics Inc.Market Sentiment Summary & Technical Entry and Exit Tips - newser.com
What technical models suggest about Dianthus Therapeutics Inc.’s comebackLayoff News & AI Based Buy and Sell Signals - newser.com
Is Dianthus Therapeutics Inc. (87E) stock at risk of policy regulationQuarterly Trade Summary & AI Forecasted Entry and Exit Points - newser.com
What Wall Street predicts for Dianthus Therapeutics Inc. stock priceNew Guidance & Smart Investment Allocation Insights - newser.com
Advanced analytics toolkit walkthrough for Dianthus Therapeutics Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Can machine learning forecast Dianthus Therapeutics Inc. recoveryWeekly Trade Summary & Weekly Stock Performance Updates - newser.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):